Corporate GovernanceJul 15, 2026, 04:22 PM
Regen BioPharma Authorizes Series N Preferred Stock with 75M Votes/Share
AI Summary
Regen BioPharma Inc. authorized a new Series N Preferred Stock, designating 1,000 shares, with each share granting holders 75 million votes. The company also settled a lawsuit with Trillium Partners, LP for $398,740, agreeing to issue Common or Series A Preferred Stock as settlement shares after court approval. Additionally, Regen BioPharma changed its independent registered public accounting firm from BCRG Group to Simon & Edward LLP, noting BCRG's prior reports included a "going concern" explanatory paragraph.
Key Highlights
- Authorized 1,000 shares of new Series N Preferred Stock.
- Series N Preferred Stock grants 75,000,000 votes per share.
- Settled lawsuit with Trillium Partners, LP for $398,740.
- Will issue Common or Series A Preferred Stock as settlement shares.
- Estimated fair market value of settlement shares is $697,795.
- Changed auditor from BCRG Group to Simon & Edward LLP.
- BCRG's prior reports noted substantial doubt about going concern.
- Trillium Partners, LP ownership limited to 9.99% of outstanding shares.
Price Impact
More from RGBP